March 26, 2024 07:00 AM EDT
Financing
Startups

Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo nabs $150M to in-li­cense more as­sets

Kyle LaHucik

Biotech Correspondent

Athena Coun­tou­ri­o­tis and her team at Aven­zo Ther­a­peu­tics have reeled in an ad­di­tion­al $150 mil­lion just two and a half months af­ter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

Pep­Gen ditch­es Duchenne pro­grams af­ter mid-stage fail, switch­es to pre­vi­ous­ly halt­ed mus­cle wast­ing ther­a­py

Ex­clu­sive: Move­ment dis­or­der biotech Vi­ma steps on­to scene with $60M

Oric locks down cash for Phase 3 prostate can­cer tri­al with ear­ly da­ta in hand

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times